Risk-Adapted Treatment of Acute Myelogenous Leukemia

Jean A. Ridgeway, DNP, APN, NP-C, AOCN®
The University of Chicago Medicine

Posted: 7/16/2018
Expires: 7/16/2019
Estimated time to complete: 1 hour and 15 minutes

This activity is supported by educational grants provided by Amgen, AstraZeneca, Celgene Corporation, Incyte Corporation, Merck Sharp & Dohme Corp., Takeda Oncology, Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Instructions for Earning CE credit

This activity has expired, credit is no longer available.


Quick Tips

How do I manage minimal residual disease?
What are the best ways to manage the side effects of AML therapies?
Copyright © 2010-2021 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.